Carcinoembryonic antigen reduction after medical treatment in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
Carcinoembryonic antigen
Colorectal cancer
Endpoint
Multimodal therapy
Prognosis
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
accepted:
27
12
2018
pubmed:
24
1
2019
medline:
8
8
2019
entrez:
24
1
2019
Statut:
ppublish
Résumé
The introduction of new drugs and multimodal treatments for the management of patients with metastatic colorectal cancer (mCRC) has reduced the importance of time-to-event endpoints and reported the attention on the response-related endpoints. Furthermore, the prognostic role of the surgical scores before the resection of metastases has not been confirmed for multimodal treatments. The purpose of this research is to perform a meta-analysis of the studies that evaluated the relationship between carcinoembryonic antigen (CEA) response and outcome in patients with mCRC receiving systemic chemotherapy. A systematic review of the literature on two databases and a selection of studies that evaluated the relationship between CEA response and outcome were performed according to predefined criteria. After, three meta-analyses were carried out on the selected studies, each for each outcome variable. Nineteen studies have been selected. Fourteen studies (1475 patients) have documented a close association between radiological response and CEA response (odds ratio (OR), 9.03; confidence intervals (CIs), 5.14-15.87; I CEA response merits further investigation as a surrogate endpoint of clinical trials of first-line medical therapy of patients with mCRC, and should be studied as a prognostic factor for those patients who are candidates for multimodal treatment strategies.
Identifiants
pubmed: 30671635
doi: 10.1007/s00384-018-03230-w
pii: 10.1007/s00384-018-03230-w
doi:
Substances chimiques
Carcinoembryonic Antigen
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Pagination
657-666Références
J Clin Oncol. 2008 Aug 1;26(22):3681-6
pubmed: 18669452
World J Gastroenterol. 2014 Jun 7;20(21):6608-14
pubmed: 24914384
World J Gastrointest Oncol. 2016 Jan 15;8(1):128-35
pubmed: 26798444
Ann Oncol. 2016 Aug;27(8):1565-72
pubmed: 27234640
Ann Surg Oncol. 2015 Jul;22(7):2262-8
pubmed: 25586242
Cancer Res. 2005 Oct 1;65(19):8809-17
pubmed: 16204051
Cancer. 1987 Apr 1;59(7):1283-8
pubmed: 3815304
Acta Med Port. 2015 May-Jun;28(3):357-69
pubmed: 26421789
Cancer Biol Ther. 2015;16(5):709-13
pubmed: 25806877
Biomarkers. 2010 May;15(3):243-8
pubmed: 20121626
Ann Oncol. 2017 May 1;28(5):1117-1123
pubmed: 28327906
Cancer Imaging. 2015 Aug 13;15:11
pubmed: 26263901
Abdom Imaging. 2015 Oct;40(8):3043-51
pubmed: 26353898
Hepatogastroenterology. 2002 Mar-Apr;49(44):388-92
pubmed: 11995458
Lancet Oncol. 2013 Nov;14(12):1208-15
pubmed: 24120480
Clin Oncol (R Coll Radiol). 2016 Oct;28(10):e155-64
pubmed: 27209207
Am J Surg. 2012 Oct;204(4):447-52
pubmed: 22481066
Clin Invest Med. 1998 Aug-Oct;21(4-5):186-91
pubmed: 9800067
J Clin Oncol. 2007 Oct 10;25(29):4575-80
pubmed: 17925551
Eur J Cancer. 2017 Jun;78:61-69
pubmed: 28412590
Int J Colorectal Dis. 2001 Apr;16(2):96-101
pubmed: 11355325
Asia Pac J Clin Oncol. 2012 Jun;8(2):172-9
pubmed: 22524576
JAMA Surg. 2015 Aug;150(8):747-755
pubmed: 26083632
Cancer. 1978 Sep;42(3 Suppl):1428-33
pubmed: 709511
Cancer. 1999 Feb 15;85(4):786-95
pubmed: 10091755
Tumour Biol. 2015 Mar;36(3):1519-27
pubmed: 25374062
Yonsei Med J. 2013 Jan 1;54(1):116-22
pubmed: 23225807
Trials. 2007 Jun 07;8:16
pubmed: 17555582
J Surg Oncol. 2013 Jul;108(1):14-8
pubmed: 23681672
PLoS One. 2007 Dec 26;2(12):e1353
pubmed: 18159236
Ann Intern Med. 1978 May;88(5):627-30
pubmed: 646245
J Clin Oncol. 2012 Dec 20;30(36):4566-72
pubmed: 23150701
J Clin Oncol. 2013 Oct 20;31(30):3764-75
pubmed: 24043732
Pharmacol Res. 2004 May;49(5):383-96
pubmed: 14998548
World J Gastroenterol. 2013 Jan 21;19(3):389-93
pubmed: 23372362
Ann Oncol. 2010 May;21(5):1013-9
pubmed: 19861580
Cancer Res. 2013 Nov 15;73(22):6584-96
pubmed: 24121495
Cancer Res. 2007 May 15;67(10):4774-82
pubmed: 17510406
Sci Rep. 2016 Dec 12;6:39028
pubmed: 27941905
Oncol Lett. 2016 Nov;12(5):4209-4213
pubmed: 27895793
PLoS One. 2016 Sep 01;11(9):e0161256
pubmed: 27583792
J Cell Physiol. 2007 Mar;210(3):757-65
pubmed: 17167768
Clin Chem. 2014 Dec;60(12):1572-4
pubmed: 25161147
J Surg Oncol. 2010 Apr 1;101(5):396-400
pubmed: 20119979
Int J Colorectal Dis. 2013 Apr;28(4):511-7
pubmed: 23208008
Ann Surg Oncol. 2015 Apr;22(4):1315-23
pubmed: 25323471
Cancer Res. 1991 Oct 15;51(20):5679-86
pubmed: 1717152
J Natl Cancer Inst. 2015 Feb 09;107(4):
pubmed: 25669203
Semin Cancer Biol. 1999 Apr;9(2):67-81
pubmed: 10202129
J Gastroenterol Hepatol. 2013 Mar;28(3):505-12
pubmed: 23216017
Cancer. 2013 Feb 15;119(4):729-38
pubmed: 23027178
Gut. 1987 Dec;28(12):1625-9
pubmed: 3428690
Br J Cancer. 2013 Feb 19;108(3):662-7
pubmed: 23322207
Acta Oncol. 2012 Sep;51(7):849-59
pubmed: 22974092
Mol Biol Rep. 2014 Jan;41(1):459-66
pubmed: 24293105
Cancer Sci. 2014 Aug;105(8):996-1001
pubmed: 24850362
Invest New Drugs. 2012 Apr;30(2):758-64
pubmed: 21057973
Cancer Invest. 2012 Jan;30(1):65-71
pubmed: 22236191
Eur J Cancer Clin Oncol. 1988 Sep;24(9):1499-503
pubmed: 3263275
Surg Today. 2015 Dec;45(12):1527-34
pubmed: 25563588
Cancer. 1979 Oct;44(4):1222-5
pubmed: 498010
Tumour Biol. 2013 Aug;34(4):2233-9
pubmed: 23625655
Clin Oncol (R Coll Radiol). 2004 May;16(3):196-203
pubmed: 15191007
Ann Surg Oncol. 2010 Apr;17(4):1010-23
pubmed: 20052553
Ann Oncol. 2002 Sep;13(9):1430-7
pubmed: 12196369